SR-4835 - 半岛电竞官方网址

您好，欢迎来到半岛游戏平台官网入口网址设备网！ [登录] [免费注册]

立即咨询

SR-4835

本半岛bd体育手机客户端不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

2387704-62-1

包装与价格：

半岛bd体育手机客户端介绍

SR-4835 是有效，高选择性和 ATP 竞争性的 CDK12/CDK13 双重抑制剂 (CDK12:IC50=99 nM，Kd=98 nM；CDK13:Kd=4.9 nM)。SR-4835 与破坏 DNA 的化学疗法和 PARP 抑制剂协同作用，并引起三阴性乳腺癌 (TNBC) 细胞凋亡。

Cas No.	2387704-62-1
Canonical SMILES	CN1N=CC(N2C3=NC(N4CCOCC4)=NC(NCC5=NC6=C(N5)C=C(Cl)C(Cl)=C6)=C3N=C2)=C1
分子式	C₂₁H₂₀Cl₂N₁₀O
分子量	499.36
溶解度	DMSO: 5 mg/mL (10.01 mM; ultrasonic and warming and heat to 60℃)
储存条件	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
半岛bd体育手机客户端描述	SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death[1]. [1]. Quereda V, et al. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. Cancer Cell. 2019 Oct 8. pii: S1535-6108(19)30424-6.